150 related articles for article (PubMed ID: 25881291)
1. Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility.
Sevlever D; Zou F; Ma L; Carrasquillo S; Crump MG; Culley OJ; Hunter TA; Bisceglio GD; Younkin L; Allen M; Carrasquillo MM; Sando SB; Aasly JO; Dickson DW; Graff-Radford NR; Petersen RC; Deák F; ; Belbin O
Mol Neurodegener; 2015 Apr; 10():18. PubMed ID: 25881291
[TBL] [Abstract][Full Text] [Related]
2. Distribution of SNAP25, VAMP1 and VAMP2 in mature and developing deep cerebellar nuclei after estrogen administration.
Manca P; Mameli O; Caria MA; Torrejón-Escribano B; Blasi J
Neuroscience; 2014 Apr; 266():102-15. PubMed ID: 24534378
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel Vamp1 splice variant in the cochlear nucleus.
Friedland DR; Eernisse R; Popper P
Hear Res; 2008 Sep; 243(1-2):105-12. PubMed ID: 18655825
[TBL] [Abstract][Full Text] [Related]
4. Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.
Zeng Y; Zhang J; Zhu Y; Zhang J; Shen H; Lu J; Pan X; Lin N; Dai X; Zhou M; Chen X
J Neurochem; 2015 Apr; 133(1):38-52. PubMed ID: 25661995
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of Alzheimer's disease and aging.
Cacabelos R; Fernandez-Novoa L; Lombardi V; Kubota Y; Takeda M
Methods Find Exp Clin Pharmacol; 2005 Jul; 27 Suppl A():1-573. PubMed ID: 16470248
[TBL] [Abstract][Full Text] [Related]
6. A null mutation in VAMP1/synaptobrevin is associated with neurological defects and prewean mortality in the lethal-wasting mouse mutant.
Nystuen AM; Schwendinger JK; Sachs AJ; Yang AW; Haider NB
Neurogenetics; 2007 Jan; 8(1):1-10. PubMed ID: 17102983
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a.
Yang Y; Kim J; Kim HY; Ryoo N; Lee S; Kim Y; Rhim H; Shin YK
Cell Rep; 2015 Aug; 12(8):1244-51. PubMed ID: 26279571
[TBL] [Abstract][Full Text] [Related]
8. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
9. Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins.
Peng L; Adler M; Demogines A; Borrell A; Liu H; Tao L; Tepp WH; Zhang SC; Johnson EA; Sawyer SL; Dong M
PLoS Pathog; 2014 Jul; 10(7):e1004177. PubMed ID: 25010769
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.
Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST
J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
12. An in vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling.
Williams RS; Bate C
Neuropharmacology; 2016 Feb; 101():566-75. PubMed ID: 26116815
[TBL] [Abstract][Full Text] [Related]
13. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
14. [Cholesterol and Alzheimer's disease].
Kálmán J; Janka Z
Orv Hetil; 2005 Sep; 146(37):1903-11. PubMed ID: 16255374
[TBL] [Abstract][Full Text] [Related]
15. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.
Folwell J; Cowan CM; Ubhi KK; Shiabh H; Newman TA; Shepherd D; Mudher A
Exp Neurol; 2010 Jun; 223(2):401-9. PubMed ID: 19782075
[TBL] [Abstract][Full Text] [Related]
16. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
17. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression.
Cummings DM; Liu W; Portelius E; Bayram S; Yasvoina M; Ho SH; Smits H; Ali SS; Steinberg R; Pegasiou CM; James OT; Matarin M; Richardson JC; Zetterberg H; Blennow K; Hardy JA; Salih DA; Edwards FA
Brain; 2015 Jul; 138(Pt 7):1992-2004. PubMed ID: 25981962
[TBL] [Abstract][Full Text] [Related]
18. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
19. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.
Tu S; Okamoto S; Lipton SA; Xu H
Mol Neurodegener; 2014 Nov; 9():48. PubMed ID: 25394486
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
